Tiantian Li1, Jian Zhou2, Xiaoling Yan3, Ran Duan4, Xiaobo Zhu2. 1. Beijing University of Chinese Medicine, No.11 Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China. 2. Ophthalmology Department, Beijing University of Chinese Medicine Affiliated Dongfang Hospital, No.6 Fangxingyuan 1st Block, Fangzhuang, Fengtai District, Beijing, 100078, China. 3. Ophthalmology Department, Beijing University of Chinese Medicine Affiliated Dongfang Hospital, No.6 Fangxingyuan 1st Block, Fangzhuang, Fengtai District, Beijing, 100078, China. yanxiaoling_369@163.com. 4. Medical Affairs Department, Beijing University of Chinese Medicine Affiliated Dongfang Hospital, No.6 Fangxingyuan 1st Block, Fangzhuang, Fengtai District, Beijing, 100078, China.
Abstract
BACKGROUND: The diagnosis of immunoglobulin G serum antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) associated inflammatory demyelinating disorders can be confirmed by the presence of MOG-IgG, yet its general cut-off concentration had not yet to be defined. Whether it is significant that a seropositive lower titer level for MOG-IgG could cause disease is still unknown. CASE PRESENTATION: A 55-year-old Chinese woman presented with acute optic neuritis manifestations in the left eye. MRI showed a left optic nerve demyelination image and a T2 hyperintensity at C7 vertebral segment without any extra specific lesions. AQP4-IgG was tested seronegative, while the MOG-IgG was positive, titer 1:10, by indirect immunofluorescence. Considering the lower concentration, we retested serum MOG-IgG after 6 months of steroid therapy, using cell-based assay, then we still got the same result which was also barely above the negative cut-off value. So, the clinical diagnose was "possible MOG-IgG-associated encephalomyelitis". The woman's condition improved by steroid therapy without relapse. CONCLUSIONS: Seropositive MOG-IgG, even at a lower level, could lead to an autoimmune inflammatory demyelination. In adults, it commonly presents as ON and myelitis. Although the patient had a considerable reaction, steroid therapy could not make MOG-IgG seronegative, instead, the antibody may persist even during remission and flare-ups can recur after steroid withdrawal. Therefore, a long-term follow-up is necessary to monitor the patient's prognosis.
BACKGROUND: The diagnosis of immunoglobulin G serum antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) associated inflammatory demyelinating disorders can be confirmed by the presence of MOG-IgG, yet its general cut-off concentration had not yet to be defined. Whether it is significant that a seropositive lower titer level for MOG-IgG could cause disease is still unknown. CASE PRESENTATION: A 55-year-old Chinese woman presented with acute optic neuritis manifestations in the left eye. MRI showed a left optic nerve demyelination image and a T2 hyperintensity at C7 vertebral segment without any extra specific lesions. AQP4-IgG was tested seronegative, while the MOG-IgG was positive, titer 1:10, by indirect immunofluorescence. Considering the lower concentration, we retested serum MOG-IgG after 6 months of steroid therapy, using cell-based assay, then we still got the same result which was also barely above the negative cut-off value. So, the clinical diagnose was "possible MOG-IgG-associated encephalomyelitis". The woman's condition improved by steroid therapy without relapse. CONCLUSIONS: Seropositive MOG-IgG, even at a lower level, could lead to an autoimmune inflammatory demyelination. In adults, it commonly presents as ON and myelitis. Although the patient had a considerable reaction, steroid therapy could not make MOG-IgG seronegative, instead, the antibody may persist even during remission and flare-ups can recur after steroid withdrawal. Therefore, a long-term follow-up is necessary to monitor the patient's prognosis.
Authors: Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Marius Ringelstein; Corinna Trebst; Alexander Winkelmann; Alexander Schwarz; Mathias Buttmann; Hanna Zimmermann; Joseph Kuchling; Diego Franciotta; Marco Capobianco; Eberhard Siebert; Carsten Lukas; Mirjam Korporal-Kuhnke; Jürgen Haas; Kai Fechner; Alexander U Brandt; Kathrin Schanda; Orhan Aktas; Friedemann Paul; Markus Reindl; Brigitte Wildemann Journal: J Neuroinflammation Date: 2016-09-27 Impact factor: 8.322
Authors: A Traboulsee; J H Simon; L Stone; E Fisher; D E Jones; A Malhotra; S D Newsome; J Oh; D S Reich; N Richert; K Rammohan; O Khan; E-W Radue; C Ford; J Halper; D Li Journal: AJNR Am J Neuroradiol Date: 2015-11-12 Impact factor: 3.825
Authors: Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker Journal: Neurology Date: 2015-06-19 Impact factor: 9.910
Authors: Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Corinna Trebst; Marius Ringelstein; Orhan Aktas; Alexander Winkelmann; Mathias Buttmann; Alexander Schwarz; Hanna Zimmermann; Alexander U Brandt; Diego Franciotta; Marco Capobianco; Joseph Kuchling; Jürgen Haas; Mirjam Korporal-Kuhnke; Soeren Thue Lillevang; Kai Fechner; Kathrin Schanda; Friedemann Paul; Brigitte Wildemann; Markus Reindl Journal: J Neuroinflammation Date: 2016-09-26 Impact factor: 8.322
Authors: S Jarius; F Paul; O Aktas; N Asgari; R C Dale; J de Seze; D Franciotta; K Fujihara; A Jacob; H J Kim; I Kleiter; T Kümpfel; M Levy; J Palace; K Ruprecht; A Saiz; C Trebst; B G Weinshenker; B Wildemann Journal: J Neuroinflammation Date: 2018-05-03 Impact factor: 8.322